Moderna weighs private market debut for COVID shot as federal funding flounders

As Congress gridlocks on funding for new COVID-19 therapies and vaccines, mRNA bigwig Moderna is setting its sights on the endemic market for its wildly successful shot, Spikevax, the biotech’s CEO has said.

“[W]hat is not clear today is, will the U.S. become a private market, which is the case for all other medicines we have access to,” Stéphane Bancel speculated in an interview with Yahoo Finance during Moderna’s 3rd annual Vaccines Day on Thursday.